Overview
Gastroenterology Regulatory Landscape
The regulatory environment for gastroenterology therapies involves specialized requirements from FDA Division of Gastroenterology and Inborn Errors Products, EMA GI Working Party, PMDA Gastroenterology Review. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ IBD clinical trial endpoint guidance
- ✓ Endoscopic and histologic endpoint requirements
- ✓ Hepatotoxicity assessment guidance (DILI)
- ✓ JAK inhibitor safety monitoring for GI indications
- ✓ Post-marketing surveillance for GI biologics
EMA Requirements
- ✓ Guideline on clinical investigation of IBD
- ✓ Endoscopic scoring requirements for UC and CD
- ✓ Liver safety assessment requirements
- ✓ PSUR expectations for GI biologics
PMDA Requirements
- ✓ Japan-specific GI drug monitoring
- ✓ IBD therapy safety assessment requirements
- ✓ Post-marketing GI surveillance obligations
ArcaScience Alignment
How ArcaScience Maps to Gastroenterology Requirements
Data Coverage
Gastroenterology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Gastroenterology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Division of Gastroenterology and Inborn Errors Products and EMA GI Working Party submission requirements.
Download
Get the Full Gastroenterology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources